Skip to main content

Table 1 Clinical Characteristics of the 12 sPGF patients

From: Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag

No. Age Sex Underlying disease Cytopenia Failed previous treatments (duration) Eltrom duration, weeks Total dose of eltrom, mg Time to CR, days Best response Last follow-up
1 21 M ALL N, PLT G-CSF, EPO, TPO, IL-11 PLT transfusion-dependent for 12 months, MSC infusion for 4 times 13 6475 43 CR Alive
2 25 F ALL N, HB, PLT G-CSF, EPO, TPO, PLT transfusion-dependent for 2 months 2 700 10 CR Alive
3 35 F ALL N, HB, PLT G-CSF, EPO, TPO, RBC and PLT transfusion-dependent for 2 months 2 700 NA PR Dead
4 22 M ALL N, HB, PLT G-CSF, PLT transfusion-dependent for 1 month 8 4200 NA NR Dead
5 52 M AML N, PLT G-CSF, IL-11, PLT transfusion-dependent for 1 month 4 700 36 CR Alive
6 27 F AML N, HB, PLT G-CSF, EPO, TPO, RBC and PLT transfusion-dependent for 3 months 7 1725 NA PR Dead
7 53 M AML N, PLT G-CSF, EPO, TPO, PLT transfusion-dependent for 1 month 6 2175 25 CR Alive
8 42 M MPAL N, HB, PLT G-CSF, EPO, TPO, RBC and PLT transfusion-dependent for 3 months; DAC for 1 course 4 1400 NA NR Alive
9 42 F SAA N, HB, PLT G-CSF, PLT transfusion-dependent for 1 month; DAC for 1 course 8 4200 30 CR Alive
10 29 F SAA N, PLT G-CSF, TPO-dependent for 1 month 23 10,500 28 CR Alive
11 33 M SAA N, PLT G-CSF, EPO, TPO, PLT transfusion-dependent for 2 months, MSC infusion for 3 times 8 4025 49 CR Alive
12 47 M MF N, PLT G-CSF, PLT transfusion-dependent for 1 month 8 2800 20 CR Alive
  1. M male, F female, N neutrophil, HB hemoglobin, PLT platelet, sPGF secondary poor graft function, AML acute myeloid leukemia, ALL acute lymphocytic leukemia, MPAL mixed phenotype acute leukemia, SAA severe aplasia anemia, MF myelofibrosis, CR complete response, PR partial response, NR no response, G-CSF granulocyte colony-stimulating factor, EPO erythropoietin, TPO thrombopoietin, MSC mesenchymal stem cell, DAC decitabine, NA not available